Unicycive Therapeutics Prepares for Significant Investor Engagements
Unicycive Therapeutics, Inc. (NASDAQ: UNCY), based in Los Altos, California, is actively making strides to engage with investors through two prominent virtual conferences ahead. This clinical-stage biotechnology firm specializes in developing innovative therapies tailored for patients battling kidney disease, aiming to reshape care in this crucial area.
Upcoming Conferences and Presentation Details
The first notable event is the Lytham Partners Spring 2025 Investor Conference, set to take place virtually. On May 29, 2025, at 12:30 p.m. ET, Shalabh Gupta, M.D., the company’s Chief Executive Officer, will host a fireside chat to provide insights into Unicycive’s latest advancements and initiatives.
Following this, on June 4, 2025, at 1 p.m. ET, Dr. Gupta will take part in the Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference. During this session, he will deliver a corporate presentation accompanied by a moderated Q&A segment, giving investors a chance to interact and delve deeper into the company’s strategic direction.
Access to Presentations
For those interested in following these exciting developments, Unicycive Therapeutics will provide live webcasts of both events. Interested parties can find links to these presentations on the Unicycive website under the Investors section, ensuring stakeholders have easy access to live updates and archived sessions.
Innovative Solutions for Kidney Disease
Unicycive Therapeutics is on the forefront of developing transformative treatments for kidney-related ailments. Their lead investigational drug, oxylanthanum carbonate, is a groundbreaking phosphate binder currently under review by the U.S. FDA. This treatment is specifically designed for patients suffering from chronic kidney disease (CKD) undergoing dialysis and aims to effectively manage hyperphosphatemia.
Additionally, Unicycive is actively working on another promising candidate, UNI-494. This investigational treatment seeks to address complications associated with acute kidney injury. Notably, UNI-494 has received orphan drug designation from the FDA to assist in preventing Delayed Graft Function (DGF) in kidney transplant patients. This treatment has successfully completed a Phase 1 dose-ranging safety study involving healthy volunteers, marking a significant milestone in its development.
Stay Informed on Unicycive Therapeutics
For continuous updates on their latest projects and research findings, stakeholders and interested parties can visit Unicycive.com. The company is also active on social media platforms such as LinkedIn and X, providing a wealth of information regarding their initiatives and industry insights.
Company Contacts for Investors and Media
For further investor inquiries, Kevin Gardner at LifeSci Advisors is the primary contact, reachable via email at kgardner@lifesciadvisors.com.
Meanwhile, for media-related queries, Rachel Visi from Real Chemistry can be contacted at redery@realchemistry.com. These contacts are instrumental in ensuring transparent communication for both investors and the media regarding Unicycive's endeavors.
Frequently Asked Questions
What is the purpose of the upcoming conferences attended by Unicycive?
The conferences aim to present Unicycive’s advancements in kidney disease treatments and engage with potential investors.
Who is the Chief Executive Officer of Unicycive Therapeutics?
Shalabh Gupta, M.D., serves as the Chief Executive Officer of Unicycive Therapeutics.
What is oxylanthanum carbonate?
Oxylanthanum carbonate is Unicycive's lead investigational drug intended for the treatment of hyperphosphatemia in patients with chronic kidney disease undergoing dialysis.
What is the significance of the UNI-494 drug?
UNI-494 is designed for treating conditions related to acute kidney injuries and has received orphan drug designation for preventing Delayed Graft Function in kidney transplant patients.
Where can we find more information about Unicycive?
For more information, visit Unicycive.com and follow the company on social media platforms like LinkedIn and X.
